| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8776829 | The Breast | 2018 | 6 Pages |
Abstract
The superiority of fulvestrant 500Â mg over fulvestrant 250Â mg in patients with LA/MBC in CONFIRM was consistent in both the first- and second-line settings for PFS, and numerically greater in both settings for OS.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, Jasmine Lichfield, Miguel Martin,